R Kim

Summary

Affiliation: Hiroshima University
Country: Japan

Publications

  1. pmc Cancer immunoediting from immune surveillance to immune escape
    Ryungsa Kim
    International Radiation Information Centre, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Immunology 121:1-14. 2007
  2. pmc Targeted therapy against Bcl-2-related proteins in breast cancer cells
    Manabu Emi
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Breast Cancer Res 7:R940-52. 2005
  3. ncbi request reprint Current and future roles of neoadjuvant chemotherapy in operable breast cancer
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
    Clin Breast Cancer 6:223-32; discussion 233-4. 2005
  4. ncbi request reprint Caspase-dependent and -independent cell death pathways after DNA damage (Review)
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Oncol Rep 14:595-9. 2005
  5. ncbi request reprint Unknotting the roles of Bcl-2 and Bcl-xL in cell death
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Biochem Biophys Res Commun 333:336-43. 2005
  6. ncbi request reprint Assay directed chemotherapy: clinical benefit remains unclear
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer Treat Rev 31:151-4. 2005
  7. ncbi request reprint Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer 103:2199-207. 2005
  8. ncbi request reprint Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer 103:1800-9. 2005
  9. ncbi request reprint Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi Minami ku, Hiroshima 734 8553, Japan
    Int J Oncol 26:1025-31. 2005
  10. ncbi request reprint Recent advances in understanding the cell death pathways activated by anticancer therapy
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer 103:1551-60. 2005

Detail Information

Publications59

  1. pmc Cancer immunoediting from immune surveillance to immune escape
    Ryungsa Kim
    International Radiation Information Centre, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Immunology 121:1-14. 2007
    ..In this review, the central roles of effector cells and cytokines in tumour immunity, and the escape mechanisms of tumour cells during tumour progression are discussed...
  2. pmc Targeted therapy against Bcl-2-related proteins in breast cancer cells
    Manabu Emi
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Breast Cancer Res 7:R940-52. 2005
    ..We examined the relationship between the expression of Bcl-2 and Bcl-xL and chemosensitivity of breast cancer cells, with the aim of developing specific targeted therapy...
  3. ncbi request reprint Current and future roles of neoadjuvant chemotherapy in operable breast cancer
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
    Clin Breast Cancer 6:223-32; discussion 233-4. 2005
    ..Herein we review the current status and future role of neoadjuvant chemotherapy in operable breast cancer in terms of its survival benefit and the potential for the individualization of adjuvant therapy for these patients...
  4. ncbi request reprint Caspase-dependent and -independent cell death pathways after DNA damage (Review)
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Oncol Rep 14:595-9. 2005
    ....
  5. ncbi request reprint Unknotting the roles of Bcl-2 and Bcl-xL in cell death
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Biochem Biophys Res Commun 333:336-43. 2005
    ..This review discusses the previously unexplained aspects of Bcl-2 and Bcl-xL functions associated with cell death, for better understanding of their functions in the regulation...
  6. ncbi request reprint Assay directed chemotherapy: clinical benefit remains unclear
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer Treat Rev 31:151-4. 2005
  7. ncbi request reprint Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer 103:2199-207. 2005
    ....
  8. ncbi request reprint Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer 103:1800-9. 2005
    ..The authors assessed the effect of STI571 on the tumor growth of gastric carcinoma in combination with 5-fluorouracil (5-FU) or paclitaxel targeting the PDGF/PDGFR-signaling pathway...
  9. ncbi request reprint Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi Minami ku, Hiroshima 734 8553, Japan
    Int J Oncol 26:1025-31. 2005
    ....
  10. ncbi request reprint Recent advances in understanding the cell death pathways activated by anticancer therapy
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer 103:1551-60. 2005
    ..The current review focused on recent advances surrounding the mechanism(s) of cell death induced by anticancer agents and discussed potential molecular targets for enhancing the chemotherapeutic effect(s) of anticancer agents...
  11. ncbi request reprint Multidisciplinary approach to cancer treatment: a model for breast cancer treatment at the M.D. Anderson Cancer Center
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 8553, Japan
    Int J Clin Oncol 9:356-63. 2004
    ....
  12. ncbi request reprint Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer 101:2491-502. 2004
    ..Here, the authors review the current clinical and preclinical evaluations of AS Bcl-2 and discuss its potential to act as a chemosensitizer and to enhance the therapeutic effect of cancer chemotherapy...
  13. ncbi request reprint Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer 101:2177-86. 2004
    ....
  14. ncbi request reprint Bax is an important determinant for radiation sensitivity in esophageal carcinoma cells
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 8553, Japan
    Int J Mol Med 14:697-706. 2004
    ..The proapoptotic gene bax plays a critical role in the determination of tumor response in radiation therapy...
  15. ncbi request reprint Role of mitochondria as the gardens of cell death
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi Minami ku, Hiroshima, 734 8553, Japan
    Cancer Chemother Pharmacol 57:545-53. 2006
    ..This review discusses the recent advancements in understanding the molecular mechanism of mitochondria-mediated cell death...
  16. ncbi request reprint Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer Biol Ther 4:924-33. 2005
    ....
  17. pmc Potential functional role of plasmacytoid dendritic cells in cancer immunity
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Immunology 121:149-57. 2007
    ..Thus, synergistically with mDCs, pDCs may also play a crucial role in mediating cancer immunity. In this review, the potential functional duality and plasticity of pDCs mediated by TLR9 ligation in cancer immunity will be discussed...
  18. ncbi request reprint Immunobiology of the sentinel lymph node and its potential role for antitumour immunity
    Ryungsa Kim
    International Radiation Information Centre, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Lancet Oncol 7:1006-16. 2006
    ..This review discusses the immunobiology of the SLN and potential strategies for activation of antitumour immunity by primary systemic chemotherapy and other modalities, in terms of tumour-size reduction and survival benefit...
  19. ncbi request reprint The role of apoptosis in cancer cell survival and therapeutic outcome
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer Biol Ther 5:1429-42. 2006
    ..This review discusses the clinical significance of apoptosis, as well as the potential contribution of other types of cell death to overall tumor sensitivity in the hopes that new therapeutic strategies might follow...
  20. ncbi request reprint Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy
    R Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer Gene Ther 14:1-11. 2007
    ..The current status and future directions of AS Bcl-2 and the potential mechanisms for multiple roles that Bcl-2 has in cancer therapy are reviewed...
  21. pmc Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity
    R Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Clin Exp Immunol 146:189-96. 2006
    ..In this review, the functional roles of tumour-associated iDCs and the strategy for targeting iDCs in effective tumour immunity for the cancer patient are discussed...
  22. pmc Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity
    Ryungsa Kim
    International Radiation Information Centre, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Immunology 119:254-64. 2006
    ..This review discusses a comparison of immunological dysfunctions in cancer and autoimmune disease with the aim of exploring new insights beyond cancer immunosuppression in tumour immunity...
  23. ncbi request reprint Extranuclear expression of hormone receptors in primary breast cancer
    R Kim
    International Radiation Information Center, Department of Pathology, Hiroshima Asa City Hospital and Hiroshima University Hospital, Japan
    Ann Oncol 17:1213-20. 2006
    ..The aim of this study was to explore the cross-talk between extranuclear expression of ER and progesterone receptor (PR) and growth factor signaling pathways in primary breast cancer...
  24. ncbi request reprint Tumor-driven evolution of immunosuppressive networks during malignant progression
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
    Cancer Res 66:5527-36. 2006
    ..In summary, tumor-derived factors drive the evolution of an immunosuppressive network which ultimately extends immune evasion from the primary tumor site to peripheral sites in patients with cancer...
  25. ncbi request reprint Potential role of HER-2; in primary breast tumor with bone metastasis
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Oncol Rep 15:1477-84. 2006
    ....
  26. ncbi request reprint The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment
    R Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi Minami ku, Hiroshima 734 8553, Japan
    Eur J Surg Oncol 32:269-77. 2006
    ..This article reviews a rational model for predicting tumour response by assessing the influence of nonapoptotic cell death, and thereby developing a more efficient strategy for enhancing the therapeutic effect of anticancer treatment...
  27. ncbi request reprint Role of the unfolded protein response in cell death
    R Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Apoptosis 11:5-13. 2006
    ..Less susceptibility to cell death upon activation of the UPR may contribute to tumor progression and drug resistance of solid tumors...
  28. ncbi request reprint Regulation and interplay of apoptotic and non-apoptotic cell death
    R Kim
    International Radiation Information Centre, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    J Pathol 208:319-26. 2006
    ....
  29. ncbi request reprint The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Cancer 100:2281-91. 2004
    ..Potential strategies for identifying which molecules can serve as targets for effective antitumor therapy also are discussed...
  30. ncbi request reprint Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Minami Ku, Hiroshima 734 8553, Japan
    Oncol Rep 11:1265-72. 2004
    ....
  31. ncbi request reprint A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: the paradoxical role of Bcl-2 oncoprotein (review)
    R Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Int J Oncol 19:1075-80. 2001
    ..Treatment with anticancer drugs should be followed by treatment with tamoxifen to produce a survival benefit from combination therapy in receptor-positive patients...
  32. ncbi request reprint Adjuvant therapy for colorectal carcinoma
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
    Anticancer Res 22:2413-8. 2002
    ..Clinical trial data suggest that the current standard regimen of adjuvant chemotherapy is a combination of 5-FU and LV for Dukes' C colon carcinoma and that radiotherapy for local control of rectal carcinoma has a survival benefit...
  33. ncbi request reprint Utility of technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 8553, Japan
    Breast Cancer 9:240-7. 2002
    ....
  34. ncbi request reprint Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy
    Ryungsa Kim
    International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi, Minami Ku, Japan
    Cancer Chemother Pharmacol 50:343-52. 2002
    ....
  35. ncbi request reprint Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
    Oncol Rep 10:145-50. 2003
    ..Weekly 1-h low-dose paclitaxel might be a therapeutically effective, safe infusion and feasible as a salvage chemotherapy for relapsed breast cancer patients following failure of prior chemotherapy...
  36. ncbi request reprint Inducing cancer cell death by targeting transcription factors
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Anticancer Drugs 14:3-11. 2003
    ..The strategy of identification of downstream target proteins or transcription factors involved in apoptosis will be necessary for the development of an effective transcription factor-targeted chemotherapy for cancer...
  37. ncbi request reprint Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Int J Oncol 22:835-41. 2003
    ....
  38. ncbi request reprint Chemosensitivity testing for gastrointestinal cancer: survival benefit potential and limitations
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Anticancer Drugs 14:715-23. 2003
    ..The clinical usefulness of individualized versus standard therapy needs to be determined. Here we discuss the potential survival benefit and current limitations of chemosensitivity testing in patients with gastrointestinal cancer...
  39. ncbi request reprint Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Minami Ku, Hiroshima 734 8553, Japan
    Int J Mol Med 11:799-804. 2003
    ..These results imply a potential new strategy targeting an antiapoptotic protein, Bcl-2, by its antisense oligonucleotide for enhancement of chemotherapeutic efficacy in undifferentiated thyroid carcinomas...
  40. ncbi request reprint Clinical relevance of meta-analysis of survival benefit when deciding treatment of adjuvant chemotherapy in gastric cancer
    Ryungsa Kim
    Department of Surgical Oncology, International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 8553, Japan
    Anticancer Res 23:1843-6. 2003
    ....
  41. ncbi request reprint Factors that influence the incidence of microscopic carcinoma in frozen and preserved specimens from patients with breast carcinoma after breast-conserving surgery
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Oncol Rep 10:1321-8. 2003
    ..The overexpression of HER-2 protein appears to play a role in EICs in positive margins, and needs to be considered for avoiding positive margins in BCS on patients with breast carcinoma...
  42. ncbi request reprint Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Oncol Rep 10:1925-30. 2003
    ..In drug-resistant cells, apoptosis is induced via DR-independent pathways mediated by mitochondrial dysfunction...
  43. ncbi request reprint Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review)
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Minami Ku, Hiroshima 734 8553, Japan
    Int J Oncol 24:5-17. 2004
    ..Herein, we review the current status of antisense therapy and its potential for enhancing anticancer drug-induced apoptosis...
  44. ncbi request reprint A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action
    R Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Minami Ku, Hiroshima 734 8553, Japan
    Oncol Rep 8:597-603. 2001
    ..These results indicate that the combination chemotherapy of the McVD-MPA may be an effective regimen to anthracycline-resistant tumor as a salvage chemotherapy to prolong the survival in the patient with relapsed breast cancer...
  45. ncbi request reprint Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer
    R Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 8553, Japan
    Int J Oncol 18:363-7. 2001
    ....
  46. ncbi request reprint Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer
    R Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Oncol Rep 8:1171-6. 2001
    ....
  47. ncbi request reprint An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer
    R Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 8553, Japan
    J Infect Chemother 6:222-8. 2000
    ....
  48. ncbi request reprint Effect of inhibitors of cysteine and serine proteases in anticancer drug-induced apoptosis in gastric cancer cells
    R Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Int J Oncol 18:1227-32. 2001
    ..The involvement of protease in signal transduction pathways may differ in cytotoxic action of drugs in gastric cancer cells...
  49. ncbi request reprint An analysis of relapsed breast cancer in patients previously treated with breast conserving surgery
    R Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
    Breast Cancer 8:146-52. 2001
    ....
  50. ncbi request reprint Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents
    Ryungsa Kim
    Department of Surgical Oncology, International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
    Surg Today 34:293-303. 2004
    ..Herein, we discuss the current status and potential for overcoming drug resistance in solid tumors and focus on the differential features of the tumor microenvironment in solid and hematologic malignancies...
  51. ncbi request reprint Significance of lymphoscintigraphic mapping with Tc-99m human serum albumin and tin colloid in sentinel lymph node biopsy in breast cancer
    R Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Int J Oncol 19:991-6. 2001
    ..The pattern and direction of the lymphatic drain to the SLN in scintigraphy need to be considered for the elimination of axillary lymph node dissection in node-negative patients with breast cancer...
  52. ncbi request reprint [A case of inoperable advanced gall bladder cancer responding to intra-arterial infusion of 5-fluorouracil (5-FU) and leucovorin (LV)]
    K Ohta
    Dept. of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
    Gan To Kagaku Ryoho 28:516-9. 2001
    ..These findings may imply that treatment with intra-arterial infusion of 5-FU and LV can be an effective chemotherapy for prolongation of survival in patients with inoperable advanced gall bladder cancer...
  53. ncbi request reprint [A new therapeutic approach to advanced and recurrent gastric cancer by TS-1]
    K Yoshida
    Dept. of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
    Gan To Kagaku Ryoho 28:1403-12. 2001
    ..These results indicate that the oral tegafur compound, TS-1, is a new therapeutic tools for advanced and recurrent gastric carcinomas, especially peritoneal disease...
  54. ncbi request reprint [Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma]
    Ryungsa Kim
    International Radiation Information Center, Hiroshima University
    Gan To Kagaku Ryoho 32:1540-5. 2005
    ..We examined the effect of antisense (AS) Bcl-2 in combination with anticancer drug for targeting therapy against Bcl-2 in gastric and breast cancer cells...
  55. ncbi request reprint [Current status and future perspectives on chemotherapy in patients with gastric cancer: can the clinical data from Japan lead to a standard international therapy?]
    R Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Nihon Geka Gakkai Zasshi 102:770-7. 2001
    ..The development of rigorous trials and personalized chemotherapy with molecular targeting are needed to achieve further survival benefit for patients with gastric cancer...
  56. ncbi request reprint Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs
    Kazuaki Tanabe
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Int J Oncol 22:875-81. 2003
    ....
  57. ncbi request reprint The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review)
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Oncol Rep 9:3-9. 2002
    ....
  58. ncbi request reprint Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Int J Oncol 20:549-55. 2002
    ....
  59. ncbi request reprint Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma
    Ryungsa Kim
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
    Anticancer Res 22:283-9. 2002
    ....